Get the Stockscreener App
14.39
1.34%
0.19
After Hours:
14.92
0.53
+3.68%
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
RCKT (Rocket Pharmaceuticals) Cash From Other Investing Act - GuruFocus.com
RCKT (Rocket Pharmaceuticals) PE Ratio without NRI : At Loss (As of Nov. 29, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Cash, Cash Equivalents, Marke - GuruFocus.com
RCKT (Rocket Pharmaceuticals) Price-to-Free-Cash-Flow : N/A (As of Nov. 28, 2024) - GuruFocus.com
RCKT (Rocket Pharmaceuticals) 50-Day SMA : $16.76 (As of Nov. 28, 2024) - GuruFocus.com
Acuta Capital Partners LLC Sells 60,370 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
3 Small-Cap Stocks That Are Ready to Rocket Higher - sharewise
Fiverr International Ltd (FVRR-N) QuotePress Release - The Globe and Mail
Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference - BioSpace
Rocket Pharmaceuticals CEO to Present at Evercore HealthCONx Conference | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock eyes $1B+ peak sales - Investing.com
(RCKT) Long Term Investment Analysis - Stock Traders Daily
Westfield Capital Management Co. LP Acquires 165,911 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Up 6.3%Time to Buy? - MarketBeat
Leerink Partnrs Has Strong Outlook for RCKT FY2025 Earnings - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Cantor Fitzgerald Reaffirms “Overweight” Rating for Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus - MSN
Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Buy Rating from Chardan Capital - Defense World
Rocket Pharmaceuticals Advances Genetic Therapies Pipeline - TipRanks
Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst - AOL
Leerink Partners Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $44.00 - MarketBeat
Rocket Pharmaceuticals' (RCKT) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Rocket Pharmaceuticals (NASDAQ:RCKT) Receives Buy Rating from Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals shares hold strong with Buy rating By Investing.com - Investing.com UK
First Turn Management LLC Purchases 60,317 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharma reports promising Phase 1 results for Danon disease therapy - Investing.com Australia
Rocket Pharma Stock Slips Despite New Long-Term Data On Phase-I Study; Retail Sentiment Slides - Asianet Newsable
Rocket Pharmaceuticals (NASDAQ:RCKT) Sets New 52-Week LowHere's What Happened - MarketBeat
Rocket Pharmaceuticals (RCKT) Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data - StreetInsider.com
Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference - Business Wire
Rocket Pharmaceuticals is Now Oversold (RCKT) - Nasdaq
When (RCKT) Moves Investors should Listen - Stock Traders Daily
Chardan Capital Has Strong Estimate for RCKT FY2024 Earnings - MarketBeat
RCKT stock touches 52-week low at $15.96 amid market challenges - Investing.com India
Rocket Pharmaceuticals' SWOT analysis: gene therapy stock faces pivotal year - Investing.com
Rocket Pharma to Present Groundbreaking Danon Disease Gene Therapy Data at AHA 2024 | RCKT Stock News - StockTitan
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Privium Fund Management B.V. Has $5.45 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Analysts Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Price Target at $51.75 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Rocke - GuruFocus.com
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference - BioSpace
Rocket Pharmaceuticals' (RCKT) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Rocket Pharmaceuticals: Q3 Earnings Snapshot - Houston Chronicle
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - Yahoo Finance
Investors Appear Satisfied With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Prospects As Shares Rocket 41% - Simply Wall St
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation - Yahoo Finance
Harbor Capital Advisors Inc. Has $3.11 Million Stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) - MarketBeat
Rocket Pharmaceuticals executive sells $51,205 in common stock - Investing.com
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):